Evidence map›Paper›PMID 26835325›Full record

ReviewTranslational pediatrics2014

The evolution of blood-spot newborn screening.

Kaustuv Bhattacharya, Tiffany Wotton, Veronica Wiley

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Progress and Prospects of Newborn Screening in China.International journal of neonatal screening · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Informing Parents about Newborn Screening: A European Comparison Study.International journal of neonatal screening · 2021
    Article
  13. Review
  14. Review
  15. Review
  16. Animal Model Contributions to Congenital Metabolic Disease.Advances in experimental medicine and biology · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kaustuv Bhattacharya1 The Children's Hospital at Westmead, NSW, Australia ; 2 Faculty of Paediatrics and Child Health, Sydney University, Australia ; 3 NSW Newborn Screening Programme, The Children's Hospital at Westmead, Australia.
Tiffany Wotton1 The Children's Hospital at Westmead, NSW, Australia ; 2 Faculty of Paediatrics and Child Health, Sydney University, Australia ; 3 NSW Newborn Screening Programme, The Children's Hospital at Westmead, Australia.
Veronica Wiley1 The Children's Hospital at Westmead, NSW, Australia ; 2 Faculty of Paediatrics and Child Health, Sydney University, Australia ; 3 NSW Newborn Screening Programme, The Children's Hospital at Westmead, Australia.
Children's Hospital at Westmead · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 50 years after the introduction of a blood-spot newborn screening test using the bacterial-inhibition assay (BIA), blood-spot newborn screening has evolved into complex public service scientific programmes. For several decades, many patients with phenylketonuria (PKU), congenital hypothyroidism (CH), cystic fibrosis (CF) and hemoglobinopathy disorders have benefited from early intervention across the world. In the last 20 years, there have been great changes in laboratory techniques and high-throughput data handling meaning that a huge spectrum of disorders can be identified from an increasing population. This coupled with the fact that there are an increasing number of therapies for specific rare disorders mean that health services may become inundated with complex and expensive demands in the future. Some of these issues have been realised in the implementation of multiplex assay such as electrospray tandem mass spectrometry (MSMS) programmes but will be much more exaggerated if genomic sequencing screening becomes a reality. In this context, the core-principles for implementation of newborn screening tests remain as important today as they have in the past when new tests are considered as part of the blood-spot screening programme.

Indexed as

congenital hypothyroidism (CH)cystic fibrosis (CF)massively parallel sequencing (MPS)Neonatal screeningphenylketonuria (PKU)tandem mass spectrometry (MSMS)

Identifiers

PMID26835325
PMCPMC4729101
OpenAlexW2144934354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.